Harpoon has developed a portfolio of novel T-cell engagers and proprietary platforms that deliver engineered proteins to direct a patient’s own immune cells to kill tumors. The company also has additional cancer drugs in early clinical trials, according to a Jan. 8 Merck news release.
The acquisition is expected to be completed in the first half of 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
